Oxford Biomedica Plc vs. Antisoma Plc - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Zwei Britische Biotechs die in der Krebsforschung tätig sind mit dem unterschied das Antisoma schon fehlschläge hatte und das geld nach aktuellen stand für max. ein Jahr reicht.
Beide Unternehmen stehen vor dem start der Phase3 Antisoma mit as1404(Lungenkrebs) in 2007 und Oxford Bio mit TroVax (Nierenkrebs) ende 2006 und (KolorektalKrebs) 2006/2007 und beide warten auf einen finanzkräftigen Partner .
Der momentane Höhenflug bei Antisoma basiert hauptsächlich auf die bevorstehende Partnernews an ich halte die Aktie auf diesem niveau für risikoreich.
Für Oxford spricht der hohe cashbestand die sehr guten resultate von TroVax bis dato und die breite Pipeline.
Auch kurzfristig stehen jede menge news bei Oxford an,einige davon schon nächste Woche.
Oxford Bio ist ein absoluter geheimtip gerade auch weil es nicht so bekannt ist wie Antisoma zumindest hier in Deutschland.
Wer wird der Outperformer der kommenden monate ? Mein favorit steht schon lange fest .


Antisoma Plc
Marktkap.:135 mio Pfund
Cash:14,9 mio pfund
kurs: 35p +2p(6,06)

Pipeline News (stand Oktober 2006)
AS1404
Positive phase II survival data in lung cancer
Promising preliminary phase II data in prostate and ovarian
cancers
Worldwide rights regained, new partner sought
Preparing for phase III trial in lung cancer


AS1411
Positive phase I data in renal cancer, including tumour responses
Granted orphan drug status in renal cancer in US and EU


AS1402
Phase I trial in breast cancer successfully completed

AS1409
Renal cancer and melanoma selected as phase I indications

1y Chart:


Homepage:
http://www.antisoma.com/home.asp

Präsentation Oktober 2006:
http://www.antisoma.com/investor_relations/documents/Antisom…

--------------

Oxford Biomedica Plc
Marktkap:150 mio pfund
Cash:38,7 mio pfund
Kurs:30,5 p +2,25p(7,96)

Pipeline News (stand September 2006):

TroVax(R) (multiple cancers)

Encouraging results from five Phase II trials in colorectal and renal
cancer presented at ASCO meeting
Phase II trial in prostate cancer fully recruited, and preliminary
analysis shows high frequency of anti-tumour immune responses
US Southwest Oncology Group secures regulatory clearance for a Phase II
trial in breast cancer
Special Protocol Assessment secured from the US FDA for Phase III TRIST
study in renal cancer
QUASAR committed to conduct a Phase III trial in early-stage colorectal
cancer
Licensing discussions at advanced stages of due diligence

MetXia(R) (pancreatic cancer)

Two dose levels of cyclophosphamide successfully evaluated in second
stage of the Phase II trial

ProSavin(R) (Parkinson\\\'s disease)

Meeting request submitted to European agency as part of regulatory
process to start clinical trials

RetinoStat(R) (retinopathy)

Preclinical preparation underway to support submission to regulatory
authorities to start clinical trials

Technology licensing

Technology licence provided to VIRxSYS for AIDS/HIV product in Phase II
trials
Strategic alliance partner, Sigma-Aldrich, launched second series of
LentiVector(R)-RNAi reagents

1y Chart:


Homepage:
http://www.oxfordbiomedica.co.uk/

Präsentation September 2006:
http://www.oxfordbiomedica.co.uk/pdfs/presentation.pdf

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.120.816 von BrauchGeld am 04.11.06 14:51:53

Antisoma




MAJOR SHAREHOLDERS

Notifier Holding

Glyn Edwards (CEO) 1,519,962

Grahame Cook 1,186,155

Dale Boden 700,278

Ursula Ney 645,391

Barry J Price 643,077

Raymond Spencer 603,231

Michael Pappas 589,071

----------------------

Oxford Biomedica




MAJOR SHAREHOLDERS

Notifier Holding

Alan Kingsman (CEO) 17,032,590

Alan G Goodman 5,083,000

Peter Nolan 487,962

Andrew Wood 185,339

Nick Woolf 165,000

Peter Johnson 100,000

Doug Jolly 50,000

Nick Rodgers 42,000

[MasterD2000]

Antwort auf Beitrag Nr.: 25.128.160 von BrauchGeld am 04.11.06 18:21:22

Mit Verlauf, die Grafik von Antisoma ist schon eine GANZE Zeit alt...

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.135.810 von MasterD2000 am 04.11.06 20:18:12

Die Grafik ist ein paar monate alt ich habe bewusst diese genommen da diese der aktuellen pipeline näher kommt als die von deren Homepage !

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.120.816 von BrauchGeld am 04.11.06 14:51:53

Hier der grund für den anstieg am Freitag !

http://news.independent.co.uk/business/analysis_and_features…

The word among small cap traders is that Oxford Biomedica, 2.5p firmer at 28.25p, is poised to report blockbuster trial results next week for its Parkinson's disease treatment. The most bullish investors believe it could even be a cure for the disease. The company is thought to have performed the trials outside the UK because of pressure from animal rights campaigners and is due to report its findings on 9 November.

[MasterD2000]

Antwort auf Beitrag Nr.: 25.145.768 von BrauchGeld am 05.11.06 11:50:50

"The most bullish investors believe it could even be a cure for the disease."

--> Wie Du schon richtig geschrieben hast: Antisoma hat schon Erfahrung mit Fehschlägen. Oxford wird sie nächste Woche auch haben, das wäre meine Meinung.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.145.899 von MasterD2000 am 05.11.06 12:04:59

Das ist gut möglich schliesslich handelt es sich hier um Biotech aber sollte die daten dennoch positiv sein dann hätte Oxford einen weiteren Blockbuster kandidat in der pipeline .

Mit einem guten Partner der laut CEO vor Jahresende noch bekannt gegeben werden soll und weitere fortschritte in der Pipeline wird diese Aktie zu diesen kursen nicht mehr erhältlich sein !

Chairman's and chief executive's report

The first half of 2006 has seen the Company achieve several of its goals for the
year. Major events included the presentation of new Phase II data with TroVax in
renal and colorectal cancer; a Special Protocol Assessment agreement from the US
Food and Drug Administration on the design and conduct of the Phase III trial of
TroVax in renal cancer; approval by the UK-based clinical trials network,
QUASAR, of a proposed Phase III trial of TroVax in colorectal cancer; and
regulatory progress towards the start of Phase I/II trials of ProSavin in
Parkinson's disease. Business development efforts have focused on the
commercialisation of TroVax, with several major pharmaceutical and biotechnology
companies currently evaluating the programme. The leading prospective partners
are in advanced stages of due diligence and are assessing the commercial
opportunity of TroVax in multiple cancer types. Discussions with these companies
on development strategies and deal structures are ongoing.

[MasterD2000]

Antwort auf Beitrag Nr.: 25.146.036 von BrauchGeld am 05.11.06 12:23:48

Da gebe ich Dir vollkommen Recht.
Antisoma wird bei weiteren guten Ergebnissen und der Meldung eines Partners ebenfalls nicht mehr so wie jetzt zu haben sein.
Vielleicht lautet dann die Überschrift besser: "Oxford & Antisoma"?

Merci aber auf jedenfall für den Hinweis mit Oxford Bio, ich kannte diese Aktie nämlich nocg gar nicht.

[Andonis1979]

Antwort auf Beitrag Nr.: 25.146.069 von MasterD2000 am 05.11.06 12:29:10

Wird das jetzt hier ein "KONKURRENZ" Thread?
Oder ein "Meine AKTIE IST BESSER ALS deine"-Thread?

Jeder investiert in das UNTERNEHMEN, von dem er überzeugt ist.

Da ich Oxford nicht kenne, werde ich da auch nicht investieren.

@BrauchGeld

Hast du mal die Adresse von Oxford?Danke...

[MasterD2000]

Antwort auf Beitrag Nr.: 25.151.387 von Andonis1979 am 05.11.06 15:30:06

@ Ansonis

Konkurrenz? Ja, nach meiner Ansicht ist dich die Überschrift dieses Threads darauf angelegt, oder täusche ich mich da?

[MasterD2000]

Antwort auf Beitrag Nr.: 25.151.387 von Andonis1979 am 05.11.06 15:30:06

Im Übrigen wird es doch wohl noch erlaubt sein in diesem Forum seine Meinung über etwas preiszugeben,ohne gleich von der Seite angemacht zu werden?

Die Adresse von Oxford Biomedica lautet:
http://www.oxfordbiomedica.co.uk/

[Andonis1979]

Antwort auf Beitrag Nr.: 25.160.386 von MasterD2000 am 05.11.06 17:48:47

Wieso seid ihr gleich immer so gereizt????
Wen hab ich denn verdammt nochmal von der SEITE angemacht?

Langsam hab ich das GEFÜHL, das sich hier viele SPINNER rumtummeln.......

[MasterD2000]

Antwort auf Beitrag Nr.: 25.160.566 von Andonis1979 am 05.11.06 17:52:54

Wird das jetzt hier ein "KONKURRENZ" Thread?
Oder ein "Meine AKTIE IST BESSER ALS deine"-Thread?

Aus diesem Satz lese ich schon heraus, dass Dir ein Posting nicht gefallen hat und Du mir das (mit Verlaub) durch die Blume mitteilen musstest. Durch die Blume heisst bei mir halt "von der Seite".

Im Übrigen sollten wir nicht über unsere Gereiztheit diskutieren sondern über die beiden Aktien, die hier im Thread als Thema vom Verfasser genannt worden sind. Und da der Thread "Oxford vs. Antisoma" genannt wurde, wird man sich wohl mit den zu erwartenden Performances der beiden Unternehmen kritisch auseinandersetzen dürfen, wobei auch die Bevorzugung einer Aktie wohl möglich sein dürfte. Es geht ja hier um eigene Meinungen. Mit Deinem Satz wird streng genommen jegliche kritische Argumentation erstickt.

So und nun ein Entschuldigung an den Verfasser, dass in Deinem Thread so ein Schmarrn diskutiert wird. Von nun an wirds von mir nur noch Postings geben, die mit dem Thema zu tun haben.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.120.816 von BrauchGeld am 04.11.06 14:51:53

Ich hab diesen Thread in erster linie eröffnet um die performance beider Unternehmen zu verfolgen.
Mir ist es egal wer wo investiert ist ich wünsche jeden viel erfolg das hier ist keine kaumfempfehlung !

News / 6 October 2006

OXFORD BIOMEDICA PRESENTS ENCOURAGING IMMUNOLOGICAL DATA FROM SIX PHASE II TRIALS OF TROVAX® IN VARIOUS CANCERS
- TroVax induces significant anti-cancer immune responses -

View Poster (871kb)

Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has presented further encouraging data from six Phase II trials of TroVax, its lead cancer immunotherapy product, at the 14th International Cancer Immunotherapy Meeting, which is sponsored by the Cancer Research Institute and the Academy of Cancer Immunology and is being held from 4-6 October 2006, in New York City.
http://www.cancerresearch.org/cancerimmunotherapy2006/index.…
The presentation comprised an analysis of immune responses induced against the 5T4 tumour antigen by TroVax in 63 patients. In addition to immunological data from two completed Phase II trials of TroVax with standard chemotherapy in colorectal cancer, the analysis included new data from four ongoing Phase II trials of TroVax alongside standard therapies in renal cancer and prostate cancer. The results showed that 84% of patients had 5T4-specific antibody responses after three injections of TroVax. 5T4-specific cellular responses were evident in 87% of patients in the two trials in colorectal cancer, and preliminary analyses also show cellular responses in the renal cancer and prostate cancer trials. These data demonstrate that TroVax can be administered both safely and also without loss of immunological efficacy in these three types of cancer alongside numerous co-medications.

Dr Mike McDonald, Oxford BioMedica's Chief Medical Officer, commented on the immunological analysis: “Stimulating a significant and sustainable anti-cancer immune response has been a challenge for the field of cancer immunotherapy. TroVax has been shown to induce consistently strong immune responses in multiple cancer settings even when administered alongside other therapies. These data confirm the breadth of potential application for TroVax and increase our confidence in its therapeutic effect as we start Phase III development.”

[Andonis1979]

Antwort auf Beitrag Nr.: 25.161.118 von MasterD2000 am 05.11.06 18:07:45

...Auweia...

[MasterD2000]

Was ich nur nicht verstehe: Oxford hat ein gutes Management, aussichtsreiche Pipeline, mehr Kapital und sucht einen Partner.

Also ziemlich mit Antisoma zu vergleichen. Aber warum läuft dann der Kurs nicht? Ist es vielleicht deshalb, dass Oxford im nächsten Jahr relativ steigende Ausgaben erwartet und Antisoma durch einen Partner diese drastisch verringern würde?

Laut Onvista verliert Oxford nächstes Jahr 70 cent pro Aktie, bei Antisoma sind es nur noch 20.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.120.816 von BrauchGeld am 04.11.06 14:51:53

Antisoma beginnt gleich mit plus in den tag ich denke hier werden bald gewinnmitnahmen einsetzen .
Oxford Bio startete erst mit leichten minus dann kamen die käufer bisher stärker gehandelt als Antisoma !

Antisoma 1d Chart:



Oxford Bio 1d Chart:

[MasterD2000]

Antwort auf Beitrag Nr.: 25.170.915 von MasterD2000 am 06.11.06 10:10:36

Antisoma:
Fundamentalkennzahlen 2005e 2006e 2007e
Ergebnis/Aktie (in EUR) -0,04 -0,09 -0,02
KGV neg. neg. neg.
Dividende/Aktie (in EUR) 0,00 0,00 0,00
Dividendenrendite (in %) 0,00 0,00 0,00

Oxford:
Fundamentalkennzahlen 2005e 2006e 2007e
Ergebnis/Aktie (in EUR) -0,04 -0,06 -0,07
KGV neg. neg. neg.
Dividende/Aktie (in EUR) 0,00 0,00 0,00
Dividendenrendite (in %) 0,00 0,00 0,00

(Onvista)

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.170.956 von MasterD2000 am 06.11.06 10:13:14

@MasterD2000

Solange ein Biotech unternehmen rote zahlen schreibt sind die Fundamentaldaten zweitrangig viel wichtiger sind patente und wie wirksam die produkte sind !

[MasterD2000]

Antwort auf Beitrag Nr.: 25.174.938 von BrauchGeld am 06.11.06 14:32:08

Das ist schon richtig, aber bei steigenden Ausgaben wird auch Oxford bald Probleme bekommen.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.176.088 von MasterD2000 am 06.11.06 15:31:56

@Master

So wie die Lage im moment aussieht steht Oxford wesentlich besser da als Antisoma das geld reicht locker bis ins jahr 2008 auch ohne Partner .

Oxford startet phase3 vor allemm der letzte abschnitt ist sehr interessant !

OXFORD BIOMEDICA commences PHASE III trial OF TROVAX IN RENAL cancer

Oxford, UK - 7 November 2006: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that the first patient has been treated in
TRIST, a pivotal multi-centre Phase III trial of TroVax, the Company's novel
cancer immunotherapy, in patients with advanced or metastatic renal cell
carcinoma (RCC).


Dr Mike McDonald, Oxford BioMedica's Chief Medical Officer, commented on the
start of the study: 'The Phase III TRIST study is designed to demonstrate
definitively that TroVax is effective as a treatment for this aggressive form of
kidney cancer. The clinical experience with TroVax in over 150 patients has
shown indications of its therapeutic potential as well as its excellent safety
profile.'


TRIST (TroVax Renal Immunotherapy Survival Trial) is a Phase III trial that is
designed to evaluate whether TroVax immunotherapy, added to first-line standard
of care therapy, prolongs the survival of patients with locally advanced or
metastatic clear cell renal carcinoma. The trial is a randomised,
placebo-controlled, two-arm study that will compare TroVax in combination with
standard of care to placebo with standard of care. The standard of care
therapies will be interleukin-2, interferon-alpha or Sutent(R) (sunitinib). The
protocol stratifies treatment between the standard of care options to ensure
that the allocation of TroVax and placebo is rigorously balanced.


Approximately 700 patients will be recruited from about 120 centres in the USA,
European Union and Eastern Europe. The primary endpoint for the trial is
survival improvement and secondary endpoints include progression-free survival,
tumour response rates and quality of life scores. The protocol includes the
appointment of a Safety and Efficacy Monitoring Board (SEMB) to assess the
safety and potential efficacy of the drug combinations at various time points
during the trial.


In May 2006, Oxford BioMedica received a Special Protocol Assessment (SPA)
agreement for the TRIST study from the US Food and Drug Administration (FDA).
The SPA process enables FDA evaluation of a trial protocol that is intended to
form the primary basis of an efficacy claim for product registration. The SPA
agreement ensures that the design, conduct, analysis and endpoints of the trial
are all acceptable to the FDA.


Oxford BioMedica anticipates rapid patient recruitment. Median survival for
patients with advanced or metastatic renal cell carcinoma is approximately 11
months. The duration of the trial will be determined by the number of survival
events (deaths) in the study group. The trial is expected to reach a conclusion
in 2008-09, which would support the Company's objective of reaching product
registration in 2009.


Commenting on the news, Oxford BioMedica's Chief Executive, Professor Alan
Kingsman said: 'The start of our first Phase III trial is an important milestone
for Oxford BioMedica and ensures that the TroVax programme is on track for
potential product registration in 2009. In addition, starting the Phase III
trial further emphasises the value of the product to potential partners.'


The Company remains committed to securing a major corporate partner for the
ongoing development and commercialisation of TroVax. As reported in September,
discussions with lead prospective partners have progressed to development
strategies and deal terms. The most advanced prospect is a major pharmaceutical
company with a leading oncology franchise that completed its due diligence on
the TroVax programme recently. Oxford BioMedica is working expeditiously with
three other global pharmaceutical companies to bring all four companies to the
same stage of discussions.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.187.363 von BrauchGeld am 07.11.06 09:45:51

Weitere gute Nachrichten für Oxford die mit ihrer Technologie hier mit an board sind!

Hier der Deal das mit Virxsys Corporation abgeschlossen wurde :
http://64.176.10.223/media/download_gallery/Aug10-2006.pdf

http://news.bbc.co.uk/1/hi/health/6120042.stm

Monday, 6 November 2006, 23:57 GMT

HIV gene therapy 'shows promise'

Preliminary tests suggest HIV infection can be treated using a disabled version of the virus itself.
Researchers at Pennsylvania University treated five patients, who had not responded to drugs, with disabled HIV.

It carried added genetic material that blocks HIV reproduction and as a result HIV levels in the patients' blood either stabilised or decreased.

The research raises the prospect that gene therapy might provide an alternative to antiretroviral drugs.

The long-term effectiveness of the drugs is under threat from the growing problem of drug resistance.


Researcher Dr Carl June said: "Gene therapy has long been discussed as an alternative treatment for HIV.

"The goal of this trial was safety and feasibility and the results established that.

"But the results also hint at something much more."

The patients selected for the trial had failed to respond to at least two antiretroviral regimens of drugs.

Own cells

They were given a single infusion of their own immune system T cells that had been removed from their blood, purified and genetically modified to carry the manipulated version of HIV.

Each patient received around 10 billion T cells - between 2% and 10% of the total number in an average person.

The disabled HIV gene used by the researchers was modified to carry an antisense RNA molecule, which scrambles the process of reading genetic information and is designed to sabotage the process HIV uses to reproduce itself inside infected cells.


Viral loads of the patients remained stable or decreased during the nine month trial - and one subject showed a sustained dramatic decrease in viral load.

T-cell counts remained steady or increased in four of the five patients.

The researchers were able to detect the modified cells in patients for months, and in some cases years after the infusion.

However, they warn that the trial was very small, and said patients would be monitored for 15 years to assess long-term effects.

Dr Bruce Levine, who also worked on the study - published online in Proceedings of the National Academy of Science - said: "Just because this has produced encouraging results in one or two patients doesn't mean it will work for everyone. We have much more work to do."

Dr George Schmid, a specialist in HIV at the World Health Organization, said it could take many years to determine whether the technique was safe and effective, but he said the results were "encouraging".

Roger Pebody, of the charity Terrence Higgins Trust, said: "Gene therapy is complex and would be a totally different strategy for HIV treatment.

"Although in its early stages, this research seems to indicate that this approach may be safe and the results are hopeful."

Edwin Bernard, editor of the journal Aids Treatment Update, said gene therapy was likely to be a labour-intensive, expensive treatment designed for individuals, and so not available to the vast majority of people with HIV/Aids who live in developing countries.

He said new drug treatments currently under development might provide an alternative.

Wider applications

It is hoped the approach could be adapted to tackle other diseases.

The researchers believe the use of viruses like HIV, lentiviruses, may prove particularly effective in gene therapy.

Lentiviruses are especially effective at infecting T cells, and also infect non-dividing or slowly dividing cells, raising the prospect that they could be used to target neurons or stem cells.

They also insert themselves into the DNA of cells in such a way that may make them safer and able to produce more long-term effects than other potential gene therapy vectors, such as adenoviruses.

The researchers are now recruiting for a second trial of the treatment - dubbed VRX496.

This time it will be tested on patients whose HIV load is already well controlled by existing drugs.

The hope is that these patients will be able to stay off their antiretroviral drugs, which do have significant side effects, for an extended period.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.191.481 von BrauchGeld am 07.11.06 13:33:27

http://uk.biz.yahoo.com/07112006/336/broker-recommendations-…

Evolution says buy Oxford Biomedica (LSE: OXB.L - news) (40p target).

1d Chart Antisoma :
32p - 3,15 p
http://uk.ichart.yahoo.com/b?s=ASM.L

1d Chart Oxford Bio:
31p + 0,50p
http://uk.ichart.yahoo.com/b?s=OXB.L

[MasterD2000]

Antisoma stellt auf Konferenz positive Ergebnisse seiner AS1404-Lungenkrebsstudie vor
8. November 2006

Neue Daten zur Tumorprogression ergänzen existierende Daten, die ein verlängertes Überleben zeigen

London, GB, und Prag, Tschechische Republik: 8. November 2006 - Antisoma plc (LSE: ASM, US OTC: ATSMY), ein auf die Entwicklung von Krebsmedikamenten spezialisiertes Unternehmen, kündigt an, dass die Endergebnisse seiner Phase-II-Studie zu AS1404 bei nicht-kleinzelligem Lungenkrebs heute auf der EORTC-NCI-AACR-Tagung in Prag von Professor Joachim von Pawel von den Asklepios Fachkliniken München-Gauting, einem der führenden Wissenschaftler der Studie, vorgetragen werden. Die endgültigen Daten hinsichtlich der Zeit bis zur Tumorprogression sind Bestandteil des Vortrags, ebenso wie die aktualisierten, im Oktober veröffentlichten Überlebenszeit- und Sicherheitsdaten.

Hier die Schlüsselergebnisse der Studie:

Patienten, die AS1404 zusätzlich zur Standardchemotherapie erhielten, wiesen eine mediane Überlebenszeit auf, die 5,2 Monate länger war (14,0 gegenüber 8,8 Monaten) als die von Patienten mit alleiniger Standardchemotherapie. Hierbei handelt es sich um einen der größten Unterschiede hinsichtlich der Überlebenszeit, der bislang von einer Studie zu einer Kombination von einem neuartigen Wirkstoff mit der Chemotherapie der ersten Wahl berichtet wurde. Die Zugabe von AS1404 senkte das Todesrisiko um 27%.
Patienten, die AS1404 zusätzlich zur Standardchemotherapie erhielten, wiesen Steigerungen um 23% sowohl hinsichtlich der medianen (5,4 gegenüber 4,4 Monaten), als auch der mittleren (6,3 gegenüber 5,1 Monaten) Zeit bis zur Tumorprogression im Vergleich zu Patienten mit alleiniger Standardchemotherapie auf. So lautet die aktualisierte und abschließende Beurteilung der an der Studie beteiligten Wissenschaftler. Diese Auswertung erfolgte, nachdem alle Patienten über mindestens 12 Monate nachkontrolliert worden waren, und zeigt eine größere Verzögerung der Progression mit AS1404 als die anlässlich der ASCO-Tagung im Juni vorgetragenen, auf Zwischenergebnissen der Studie basierenden Daten.
Patienten, die AS1404 plus Standardchemotherapie erhielten, wiesen eine Tumoransprechrate von 31% auf, im Vergleich zu 22% bei Patienten mit alleiniger Chemotherapie (berichtet auf der ASCO-Tagung im Juni 2006).
Die Ergebnisse zur Sicherheit waren bei beiden Gruppen weitgehend vergleichbar: 16 Patienten, die AS1404 erhielten, zeigten schwere unerwünschte Ereignisse im Vergleich zu 17 Patienten mit alleiniger Chemotherapie.
Professor von Pawel sagte: „Es besteht ein offenkundiger Verbesserungsbedarf bei der Behandlung von nicht-kleinzelligem Lungenkrebs. AS1404 ist ein vielversprechender und neuartiger Ansatz, und ich freue auf eine Mitwirkung beim Phase-III-Programm.”

Dr. Ursula Ney, Chief Operating Officer bei Antisoma, sagte: „Wir haben fünf Wirksamkeitsmaße im Rahmen von drei Phase-II-Studien bei verschieden Krebsarten untersucht, und bei allen zeigten sich Verbesserungen, wenn AS1404 als Zusatz zur Standardchemotherapie verabreicht wurde. Damit befinden wir uns in einer hervorragenden Position bei unseren Bemühungen, einen Lizenzvertrag abzuschließen und die Phase-III-Entwicklung vorzubereiten.”

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.197.569 von BrauchGeld am 07.11.06 17:58:10

1d Chart Oxford Bio (30,75p)


1d Chart Antisoma (35,46p)

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.250.268 von BrauchGeld am 09.11.06 23:07:34

Oxford präsentiert auch positive ergebnisse auf der EORTC tagung:

Oxford, UK – 9 November 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that Dr. Robert Amato has presented further encouraging data from three Phase II trials of TroVax, the Company’s lead cancer immunotherapy product, in renal cell carcinoma and prostate cancer at the 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", which is being held on 7-10 November 2006 in Prague, Czech Republic. http://www.fecs.be/emc.asp?pageId=973&Type=P

Dr. Amato of the Genitourinary Oncology Centre, the Methodist Hospital in Houston, USA, is the Principal Investigator for two ongoing Phase II trials of TroVax in renal cell carcinoma (RCC) and a Phase II trial of TroVax in prostate cancer.

The RCC trials are designed to evaluate the safety, immunogenicity and effectiveness of TroVax as a single agent and in combination with standard therapy of interleukin-2 (IL-2) or interferon-a (IFN). The regimen comprises seven intramuscular injections of TroVax over 41 weeks. To date, the two trials have enrolled 33 patients with progressive metastatic RCC and 18 patients are currently receiving therapy. All patients were heavily pre-treated before entering the trials. Dr. Amato presented data showing that TroVax was well tolerated and has shown promising anti-tumour activity in this patient group. One patient had a complete response (tumour eradication) and two patients developed a partial response (tumour shrinkage). A further 15 patients showed disease stabilisation for periods exceeding three months, including one patient that has been stable for more than 46 weeks. Overall survival in the two studies is too early to assess and has yet to reach a median. The immunological analysis is ongoing but a preliminary assessment has shown that TroVax induced 5T4-specific antibody responses in more than 90% of evaluable patients. Importantly, in patients with clear cell RCC, there was a statistically significant correlation (p=0.028) between the immune response to 5T4 and clinical benefit based on changes in patients’ tumour burden. This is particularly encouraging since it supports the rationale that the 5T4-specific immune response induced by TroVax has therapeutic benefit. Clear cell RCC is the most common subtype of renal cancer and is the patient group for the Phase III TRIST study.

The Phase II trial in prostate cancer is similarly designed to evaluate the safety and immunogenicity of TroVax as a single agent and in combination with standard therapy of GM-CSF. The regimen comprises ten intramuscular injections of TroVax over 45 weeks. The trial has enrolled 27 patients with hormone-refractory prostate cancer and eight patients continue to receive therapy. TroVax was well tolerated and all patients developed a strong 5T4-specific antibody response whether or not they received GM-CSF. Analysis of cytotoxic T-cell immune responses stimulated by TroVax in the renal and prostate cancer trials is ongoing.

Dr Mike McDonald, Oxford BioMedica’s Chief Medical Officer, commented on the new data: “We are very encouraged by the data emerging form these Phase II trials. The data provide further evidence that TroVax can be administered safely and that it induces consistent antibody responses to the target tumour antigen 5T4. The correlation between immune and clinical responses supports our Phase III development strategy of TroVax in renal cancer”.

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.344.492 von BrauchGeld am 12.11.06 19:29:38

Die Prosavin ergebnisse sollen morgen vorgestellt werden !

Snippet in the Independent today:
Watchers of the biotechnology group Oxford Biomedica will be on the lookout for news over the weekend. One of its scientists is due to talk in Athens at which he is expected to give an update on Prosavin, the company's Parkinson's disease treatment. The stock closed 0.5p better at 31.25p.

[strojo]

Antwort auf Beitrag Nr.: 25.344.874 von BrauchGeld am 12.11.06 19:38:16

ProSavin
®
Oxford BioMedica’s lead neurotherapy product candidate, ProSavin, is a novel approach to
the treatment of Parkinson’s disease, which directly targets the cause of disease symptoms.
ProSavin uses a LentiVector system to deliver the genes for three enzymes that are required
for the synthesis of dopamine. The product is administered locally to the striatum, converting
cells into a replacement dopamine factory within the brain.
A confirmatory long-term preclinical efficacy study is ongoing in an industry-standard model of
Parkinson’s disease. The study has previously confirmed that a single treatment with ProSavin
has a statistically significant (p<0.05) therapeutic effect after two weeks, and restores almost
normal movement after five to eight weeks. Recent data show that the therapeutic benefit has
been maintained to the latest time point of twelve months. Furthermore, long-term ProSavin
treatment gave improved benefit in reducing symptoms without any side-effects when
compared with the conventional treatment of L-Dopa. Results from this and other preclinical
proof of principle studies will shortly be submitted for publication in a medical journal. The new
data are also expected to be presented at the European Society of Gene Therapy Annual
Meeting in Athens, Greece, in November 2006.
In the first half of 2006, the manufacturing process was optimised for production scale-up and
transfer to a facility that is in compliance with Good Manufacturing Practice (GMP). The
manufacture of GMP clinical material is expected to start in the second half of 2006. In July
2006, the Company submitted a formal meeting request to a European agency as part of the
regulatory process leading to approval for clinical trials. The proposed Phase I/II trial is to
evaluate ProSavin in patients with moderate to late-stage Parkinson’s disease

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.350.830 von strojo am 12.11.06 21:59:38

Oxford liefert positive daten !

Oxford Biomedica PLC
13 November 2006





OXFORD BIOMEDICA PRESENTS ENCOURAGING PRECLINICAL EFFICACY
DATA WITH PROSAVIN(R) IN PARKINSON'S DISEASE


- Presentation at the 14th Annual Congress of the European Society of Gene
Therapy, 9-12 November 2006, in Athens, Greece -

Oxford, UK - 13 November 2006: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announced today that new preclinical efficacy results with its
gene-based product for Parkinson's disease, ProSavin, were presented at the 14th
Annual Congress of the European Society of Gene Therapy (ESGT) in Athens,
Greece, which was held on 9-12 November 2006 (
http://www.esgt.org
). The data
showed, for the first time, that ProSavin outperformed the standard treatment
for Parkinson's disease, L-DOPA, in terms of efficacy without inducing any of
the disabling dyskinesias (movement disorders) that occur following prolonged
treatment with L-DOPA. Also, long-term data showed that ProSavin's therapeutic
benefit was maintained for at least 15 months, the most recent time point,
without any loss of effect.


ProSavin is administered locally to the region of the brain called the striatum,
delivering the genes for three enzymes that are required for the synthesis of
dopamine. These genes are able to reprogram the cells that they enter, enabling
these cells to manufacture and secrete dopamine. The treated brain region
becomes a new endogenous source of dopamine, replacing the patient's own lost
source of the neurotransmitter. Sustained expression of the genes is a key
requirement for the product to be clinically successful.


Dr Palfi, Head of Neurosurgery at Henri Mondor Hospital, Creteil is the
principal researcher conducting the preclinical in vivo evaluation of ProSavin.
At the ESGT meeting, Dr Palfi presented a comparison of ProSavin with L-DOPA in
an industry standard model of Parkinson's disease. In the early stages of
treatment, ProSavin gave high levels of efficacy when evaluated by a series of
clinically relevant parameters. In addition, the benefit of a single
administration of ProSavin was maintained after a prolonged period, whereas the
benefit of continuous L-DOPA therapy waned significantly. Dr. Palfi reported
that ProSavin has been effective to the most recent time point of 15 months.


The higher efficacy of ProSavin combined with the absence of side effects
suggest that ProSavin could be used to replace current standard therapy with
L-DOPA in late-stage Parkinson's disease. These new data add to the extensive
preclinical data package that supports advancement of the product into human
trials.


Oxford BioMedica is planning to start a European Phase I/II trial of ProSavin in
2007 in patients with late-stage Parkinson's disease and has proposed a clinical
plan to progress to a Phase III trial following success in the Phase I/II trial.
The Phase III trial, which is designed to support product registration, could
commence in 2009. Discussions with relevant regulatory agencies are ongoing.


Commenting on the ProSavin data, Oxford BioMedica's CEO, Professor Alan Kingsman
, said: 'These new results substantially strengthen the already impressive
preclinical data set for ProSavin and confirm its potential as a treatment for
Parkinson's disease, particularly when other therapies fail. Its duration of
action and lack of side effects are particularly promising. We are now working
towards the start of human trials and have been encouraged by discussions with
the regulatory agencies.'

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.355.312 von BrauchGeld am 13.11.06 10:28:45

BBC,Daily Mail usw. alle berichten heute über Trovax von Oxford !

http://www.thisislondon.co.uk/news/article-23374255-details/…

Vaccine for kidney and bowel cancers 'within three years'
13.11.06

A revolutionary cancer vaccine developed by UK scientists can destroy and shrink deadly tumours by using the body's own immune system, it has emerged.

In trials the jab has surpassed expectations, sparking hopes it could prove an effective treatment for cancers that strike tens of thousands of Britons each year.

One patient given the vaccine has seen his tumour disappear completely for more than six months.

Another two have seen their tumours shrink, and in three people the cancer has been halted in its tracks.

The researchers said results were 'exciting' and 'very encouraging'.

Oxford BioMedica, the British company behind the jab, is initially hoping it will provide a new treatment for kidney and bowel cancer.

Between them these cause 40,000 new cases and 20,000 deaths each year in the UK.

To date 150 patients have had the vaccine and 95 per cent of those that can be evaluated have had an 'anti-tumour response'.

If further trials prove successful, the vaccine could be licensed for use against kidney cancer within just three years.

Experts last night said the data suggests the 'gene therapy' vaccine could prove an effective treatment for a whole range of cancers. The new jab called TroVax works in a totally different way to existing treatments by harnessing the patient's own immune system to fight the disease.

The patient is given a series of injections in the arm containing a harmless virus and a gene for a protein called 5T4.

This protein is found on the surface of tumours but not on healthy cells.

By injecting the gene into the body, it triggers an immune system reaction which kills the cancer cells but leaves healthy tissue unharmed.

Data from an early trial involving 34 people with kidney cancer were revealed at a major American cancer conference earlier this year. Last week updated data was announced at a medical conference in Prague from the Phase II trial, in which people with renal cell carcinoma had the vaccine on its own or in combination with other standard treatments.

Renal cell carcinoma is a particularly aggressive form of kidney cancer which accounts for more than 80 per cent of the 6,000 cases of kidney cancer diagnosed each year in the UK and claims 3,400 lives annually.

Among the 18 given the treatment along with a drug called interleukin-2, one patient saw his tumour totally disappear.

Two patients have seen it reduce in size - one to the point where it can no longer be seen in his latest scan.

In another three their disease has been stable for more than three months with one patient finding his disease has halted for more than 46 weeks.

Dr Bob Amato, who led the US trials, said the trial was primarily designed to show the vaccine was safe and produced an immune system reaction.

To see that it was also helping shrink or halt the growth of tumours in some patients was an unexpected bonus.

'To find we are already seeing this kind of activity when it is not the primary objective makes it exciting,' he said.

'In some cases we have seen very significant responses.'

Among the kidney cancer patients, the vaccine only appears to work for the most common type known as 'clear cell renal cell carcinoma'. Those with a form known as 'papillary renal cell carcinoma' did not respond to the treatment during the trials.

The studies are still at an early stage and the latest results have not yet been published in a peer-reviewed journal.

But based on their success, a much larger study involving 700 patients around the world including dozens from the UK with this kind of kidney cancer is now being launched.

All patients will have had surgery to remove the tumour and they will then receive the jab, or a placebo, alongside with three different standard drug treatments.

Professor Robert Hawkins who is now starting the latest phase of trials at the Christie Hospital in Manchester, said the data from the phase II trials was 'very encouraging.'

'It would be rare that a patient would get rid of a tumour with standard treatment,' he said. 'The fact it has happened in a relatively small trial is encouraging.

'We hope this treatment will improve the outcome of patients and that is why we need larger trials with hundreds to prove whether this combination is better than existing treatments and causes no unexpected side effects.'

Dr Daljit Kaur, clinical trials research manager at Cancer Research UK, said TroVax developed out of original research by Manchester scientists who were funded by the charity.

'The data so far suggests TroVax could be an effective treatment for several types of cancer, including kidney cancer, which affects more than 6,600 people each year in the UK,' he said.

Oxford BioMedica was established in 1995 as a spin-out from Oxford University and specialises in the development of gene-based treatments.

Its Chief Medical Officer Dr Mike McDonald said: 'The clinical experience with TroVax in over 150 patients has shown indications of its therapeutic potential as well as its excellent safety profile.'

[BrauchGeld]

Antwort auf Beitrag Nr.: 25.358.257 von BrauchGeld am 13.11.06 13:55:17

Die öffentlichkeit wird endlich auf Oxford aufmerksam ,heute stieg die aktie um kanpp 7% auf 33,25p !

http://news.bbc.co.uk/1/hi/health/6142764.stm

Last Updated: Monday, 13 November 2006, 10:50 GMT

E-mail this to a friend Printable version

Vaccine 'tackles kidney cancer'


A vaccine which uses the body's immune system to attack an aggressive form of kidney cancer has completely eradicated one patient's tumour.
The TroVax vaccine, made by Oxford Biomedica, has been given to 150 patients so far in clinical trials.

Another two patients have seen their tumours shrink, and a further 15 have been stable for at least three months.

UK cancer experts said the data, presented at a conference in Prague, showed TroVax was effective.

Around 6,600 people are diagnosed with kidney cancer each year in the UK. In 2004, 3,600 people died from the condition.

The TroVax vaccine is still going through the clinical trials process.

It works by harnessing the body's immune system to tackle a tumour.

A protein called 5T4 is present on the surface of around 90% of kidney tumours, but not on healthy cells.

The patient is given a series of injections containing a harmless virus and a gene for the 5T4 protein.

This gene triggers an immune reaction which leads the body to attack the cancer cells.

The treatment involves seven injections over 41 weeks, given alongside standard cancer therapy.

Quality of life

The patient who saw his tumour completely disappear was given the vaccine plus a drug called IL-2, already given as standard treatment for kidney cancer.

Of the 15 patients whose disease stabilised, one has been stable for 46 weeks.

A further 700 patients will now receive the treatment as the vaccine undergoes further study.

The Phase III trial will compare TroVax plus standard kidney cancer treatment and a dummy version plus standard treatment.

Researchers will look at whether or not tumour shrink, if the progression of the disease can be halted and patients' quality of life.

Professor Robert Hawkins, of Christie Hospital in Manchester who will be leading the study, said the data so far on the vaccine was "very encouraging".

"It would be rare that a patient would get rid of a tumour with standard treatment.

"The fact that it has happened in a relatively small trial is encouraging."

Dr Daljit Kaur, clinical trials research manager at Cancer Research UK, said: "We're very pleased that TroVax has entered phase III clinical trials for treating kidney cancer.

"The data so far suggests TroVax could be an effective treatment for several types of cancer, including kidney cancer, which affects more than 6,600 people each year in the UK."

Oxford Biomedica hope the vaccine will be available for use by the end of the decade.

[MasterD2000]

Am 6. Dezember vollzog das Unternehmenden ersten Schritt desADR-Programmes.


Dies ermöglicht US-Investoren Antisoma in einer Dollar-nominiertenUmgebung zu handeln, und es istals erster Schritt hin zu einemregulären Listingder Antisoma-Aktien an der NASDAQ zu verstehen.


Handelssymbol: ATSMY
CUSIP-Nummer: 03718Q109
Verhältnis: 1 ADR : 20 normale Antisomaaktien


Als Depotbank für die ADR-Zertifikate hat Antisoma The Bank of New Yorkgewählt.


Für weitere Informationen bitten wir Sie, sich direkt mit der Bank in Verbindung zu setzen:

Tel: [phone]


Tel from the US: 1 888 269 2377 (1 888 BNY ADRS)





E-Mail: [e-mail]

[MasterD2000]

Hier kann man mal auf Englisch das letzte Webcast von Antisoma anhören (corporate intro)

http://www.wsw.com/webcast/rrshq10/aioaf.pk/

[MasterD2000]

Oxford, UK – 8 December 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for TroVax for the treatment of patients with renal cancer in the European Union (EU). The COMP is part of the European Medicines Agency (EMEA). Final adoption of the opinion is expected from the European Commission in early 2007.

European orphan drug designation ensures a ten-year marketing exclusivity for TroVax within the EU. In addition, Oxford BioMedica and its prospective partner will benefit from a simplified, accelerated and cost-effective approval procedure under the consultative guidance of the EMEA. The Company plans to request the equivalent orphan drug status in the USA.

EU orphan drug designation was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect not more than 5 in 10,000 persons in the EU. Renal cancer represents any malignant tumour with its origin in the tissues of the kidneys. More than 150,000 people are newly diagnosed with renal cancer worldwide each year. Prognosis is very poor. If renal cancer has metastasised to other organs at the time of first diagnosis, the five-year survival rate is less than 5%. In the USA and Europe, renal cancer accounts for more than 33,000 deaths each year. Data from IMS suggest that over 5,000 patients in the UK received treatment for metastatic renal cancer in 2005.

Dr Mike McDonald, Oxford BioMedica’s Chief Medical Officer, commented on the news: “This positive recommendation from the EMEA for orphan drug designation adds further momentum to the development of TroVax. It underscores the need for effective treatments for renal cancer, where treatment options are limited and the prognosis is poor.”

Oxford BioMedica commenced a pivotal multi-centre Phase III trial of TroVax in renal cancer in November 2006. The Phase III trial, denoted TRIST (TroVax Renal Immunotherapy Survival Trial), is designed to evaluate whether TroVax immunotherapy, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal carcinoma. Approximately 700 patients will be recruited from about 120 centres in the USA, EU and Eastern Europe. The primary endpoint for the trial is survival improvement. Oxford BioMedica received a Special Protocol Assessment agreement for the TRIST study from the US Food and Drug Administration (FDA). The trial is expected to reach a conclusion in 2008-09, which would support the Company’s objective of reaching product registration in 2009 in the USA and 2010 in the EU.

Oxford BioMedica has a key strategic objective of securing a major corporate partner for the ongoing development and commercialisation of TroVax. The Company has progressed to negotiations of terms with its lead prospective partners and remains committed to finalising a deal expeditiously.

[MasterD2000]

Antisoma advancing AS1411 into phase II in acute myelogenous leukaemia; positive supporting data presented at ASH
11 December 2006

London, UK, and Orlando, FL, 11 December 2006 – Antisoma today announces that it is advancing AS1411 into a phase II trial in acute myelogenous leukaemia (AML). AS1411 will be tested in combination with cytarabine (Ara-C), an established treatment for AML. The trial is expected to include older patients being treated for the first time and patients of any age who have suffered a relapse after initial treatment. Antisoma plans to start the study in 2007. It will run in parallel with a separate phase II trial of AS1411 in renal cancer.

Positive data supporting the development of AS1411 in AML were presented yesterday at the American Society of Hematology (ASH) meeting in Orlando, Florida. The presentation included work by Antisoma scientists and by a team from the Medical University of South Carolina in Charleston, SC, who worked with cells from leukaemia patients.

Key themes covered in the presentation were:

Potential to target AML with AS1411 – Killing of cancer cells by AS1411 is dependent on those cells expressing the drug’s target, nucleolin, on the cell surface. AML blast cells from cancer patients were shown to express high levels of nucleolin and 100% of cells in each of three AML cell lines expressed the protein on their surface. This suggests that AML cells will be targeted by AS1411 following intravenous dosing.

Potential for AS1411 efficacy in AML – AML blast cells from patient blood and bone marrow samples were efficiently killed by AS1411. Killing was also seen in a variety of AML cell lines. Initial findings suggest a sensitivity of AML cells similar to or better than that seen in a renal cancer cell line, which is encouraging given the responses seen in renal cancer patients in AS1411 trials.

Safety margin for AS1411 treatment in AML – Normal B cells (white blood cells) from volunteers were tested for sensitivity to AS1411. Concentrations substantially higher than those lethal to AML blasts and cell lines were not toxic to these normal cells. This is consistent with the remarkable scarcity of side effects seen with AS1411 in the clinic.

Potential to combine AS1411 with current AML treatments – AS1411 showed synergistic killing of an AML cell line when combined with cytarabine (Ara-C), one of the established treatments for AML. This finding will be applied directly in the forthcoming clinical trial, where AS1411 will be used in combination with cytarabine.

Dr Daniel Fernandes, Antisoma’s lead collaborator at the Medical University of South Carolina, said: “The findings with AS1411 in AML patient cells are really promising, and it will be very interesting to see the results from the AML clinical trial.”

Glyn Edwards, Antisoma’s CEO, said: “AS1411 is a novel drug with potential against a wide variety of cancers. Our phase II plans in AML reflect our broadening of the development programme as we build on the excellent safety profile and exciting signs of activity seen in phase I.”

The poster presented at the ASH meeting is available on Antisoma’s website at www.antisoma.com

[BrauchGeld]

Antwort auf Beitrag Nr.: 26.098.974 von MasterD2000 am 11.12.06 10:35:15

Ein kleiner Artikel das am vergangenen samstag erschienen ist das sicherlich zu den kursanstieg beigetragen hat .


Item in the FT smaller companies "Renal cancer lift for Oxford Bio"
By Alan Cane Published: December 9 2006. Good news all round. The volume and the price rise show that OXB are now being taken seriously; if the Trovax deal is a good one, and with the competition to secure then it should be the very best OXB can extract, then IMO we could see a share price of one pound fairly quickly. But don't sell then. Wait for Prosavin to take us into a multi pound rating.

5D Chart Oxford Bio:


5D Chart Antisoma:

[Erbse1]

Glaxosmithkline licences Lentivector technology

Oxford BioMedica and Sigma-Aldrich have signed a joint licence agreement for LentiVector technology with GlaxoSmithKline (GSK), which provides GSK with access to the technology for research activities
Sigma-Aldrich is Oxford BioMedica's strategic partner and exclusive licensee in the commercialisation of the LentiVector technology for research use. Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types. The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.

Oxford BioMedica has a comprehensive portfolio of US and European patents and applications that cover the technology.

The company has an active licensing programme providing access to its LentiVector technology on a non-exclusive basis primarily.

Licensees include Biogen Idec, Merck, and Pfizer.

Commenting on the news, Oxford BioMedica's senior vice president commercial development, Peter Nolan, said: 'We are delighted to have secured another licensee for the LentiVector gene delivery technology and we welcome GlaxoSmithKline to our portfolio of users'.

'The industry is adopting our technology as the gold standard for various applications in research and drug discovery.

'With our strategic partner, Sigma-Aldrich, we are well positioned for further penetration of the research field with our technology'.

Shaf Yousaf, president of the Sigma-Aldrich research biotechnology business unit said: 'This is the first joint licensing agreement with Oxford BioMedica and we expect this to be a model for other such agreements under our strategic alliance.

'As market leader in this field, we believe Oxford BioMedica's LentiVector technology has a substantial commercial opportunity as a research tool.'

Quelle: http://www.laboratorytalk.com/news/ofo/ofo183.html

Schönen Tag noch
Erbse

[MasterD2000]

Antwort auf Beitrag Nr.: 26.487.243 von Erbse1 am 27.12.06 07:53:29

OXFORD BIOMEDICA REPORTS AVIAN TRANSGENIC MILESTONE: INTERFERON ALPHA EXPRESSED IN EGGS
Oxford, UK - 24 January 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and its collaborative partners in the field of avian transgenics, Viragen, Inc. (AMEX: VRA) and Roslin Institute, today announced a new achievement with the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the OVA™ System (Avian Transgenic Biomanufacturing). This is the third therapeutic protein expressed thus far in a series of “proof-of-principle” studies, which aim to develop the OVA™ System as a novel, large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins. Viragen holds the worldwide exclusive license to commercialise Avian Transgenic Technology as granted by Roslin Institute.

Alpha interferon is a protein produced by the human immune system that is fundamental to the body’s resistance to disease. This OVA™-expression study produced interferon alpha-2a, which is the active ingredient in Roferon®-A (Roche), a drug approved for the treatment of certain chronic infectious diseases and cancers. Importantly, the team has previously demonstrated that the OVA™ System can repeatedly target expression to the oviduct and incorporation in the egg, rather than being expressed throughout the bird, plus the characteristic of protein drug expression is able to be passed to subsequent generations. This combination of features is essential for a viable and cost-competitive manufacturing system.

Viragen has previously reported successful OVA™-expression of a humanised monoclonal antibody it is developing for advanced malignant melanoma and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of Multiple Sclerosis (MS), as Avonex® (Biogen Idec) and Rebif® (Merck Serono).

The Project’s Scientific Leader, Dr. Helen Sang of Scotland’s Roslin Institute, commented, “With each new functional protein that we recover from transgenic hens’ eggs, synthesised as a component of the egg white, we significantly advance our collective knowledge and experience. We have now demonstrated synthesis of three different proteins at a consistent level and will move on to characterize OVA™-expressed interferon alpha to further refine and optimise the technology.”

According to Vice President and Managing Director of Viragen (Scotland) Ltd., Dr. Karen Jervis, the OVA™ System production method differs dramatically from standard interferon manufacturing methods. “Typically, single-subtype, recombinant alpha interferon is manufactured in bacterial or mammalian cells in bioreactors housed in complex and costly facilities. With the OVA™ System, we expect to offer large-scale manufacturing capabilities in a setting far less capital-intensive and with high levels of efficiency and quality. Most importantly, OVA™-expressed proteins will need to adhere to extremely stringent quality standards, and we are proceeding with comprehensive internal and external studies to fully characterize the proteins we express through biochemical and functional testing. These data, if positive, will be pivotal in preparing both a compelling economical model and a safety/quality case for the regulatory authorities.”

“I congratulate the Viragen, Roslin and Oxford BioMedica teams that all played key roles in adding another therapeutic candidate to our portfolio of OVA™-expressed proteins,” stated Viragen’s President and CEO, Charles A. Rice. “This alliance continues to pioneer advancements in the field of transgenic hen protein production, and as we gather additional supporting evidence, we will pursue strategies designed to expedite a regulatory pathway for one candidate, which we expect to ultimately lead to key commercial licenses.”

Professor Alan Kingsman, Oxford BioMedica’s Chief Executive Officer, commented: “The collaboration with Viragen and the Roslin Institute to develop an effective avian transgenic system for biomanufacturing goes from strength to strength. This milestone further demonstrates the commercial potential of this technology.”

[MasterD2000]

mal noch was nachgereicht vom 16.1.07:

OXFORD BIOMEDICA ANNOUNCES PUBLICATION OF AVIAN TRANSGENIC RESULTS IN LEADING U.S. SCIENTIFIC JOURNAL

Oxford, UK - 16 January 2007: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and its collaborative partners in the field of avian transgenics, Viragen, Inc. (AMEX: VRA) and Roslin Institute, today announced that the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a leading scientific journal, has published an article profiling the avian transgenic (OVA™) system’s ability to express two therapeutic proteins in the whites of eggs of transgenic hens. The OVA™ System is being developed as a novel, large-scale biomanufacturing alternative, capable of cost-effectively expressing many types of therapeutic proteins.

The article, entitled, “Oviduct-specific expression of two therapeutic proteins in transgenic hens”, reports on the production of two protein drug candidates: a humanized monoclonal antibody being developed by Viragen for advanced malignant melanoma and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of Multiple Sclerosis (MS), as Avonex® (Biogen Idec) and Rebif® (Serono).

Article Summary:
Recent advances in avian transgenesis have led to the possibility of utilizing the laying hen as a production platform for the large-scale synthesis of pharmaceutical proteins. Ovalbumin constitutes more than half of the protein in the white of a laid egg, and expression of the ovalbumin gene is restricted to the tubular gland cells of the oviduct. Here we describe the use of lentiviral vectors to deliver transgene constructs comprising regulatory sequences from the ovalbumin gene designed to direct synthesis of associated therapeutic proteins to the oviduct. We report the generation of transgenic hens that synthesize functional recombinant pharmaceutical protein in a tightly regulated tissue-specific manner, without any evidence of transgene silencing after germ-line transmission.

According to Viragen Vice President, Dr. Karen Jervis, who is Managing Director of Viragen’s Scotland operations, additional avian transgenic milestones are expected shortly: “We are very pleased that the PNAS article chronicles our ‘proof-of-principle’ studies resulting in successful germline transmission of two therapeutic proteins, and we expect to report excellent new results with a third protein-drug candidate by the end of this month, assuming positive confirmations,” stated Dr. Jervis.

Professor Alan Kingsman, Oxford BioMedica’s Chief Executive Officer commented: “We are delighted by the progress of our collaborative partners towards the commercialisation of the OVA™ System. This technology could address a substantial need in the biopharmaceutical industry for efficient, high-volume production of biological products.”

[BrauchGeld]

Antwort auf Beitrag Nr.: 27.146.814 von MasterD2000 am 24.01.07 11:53:56

Oxford Biomedica (LSE: OXB.L - news) (rumours of a 70 pence-a-share bid approach, possibly from
GlaxoSmithKline (LSE: GSK.L - news) )

[Erbse1]

Operational highlights:

TroVax(R) (cancer)

• Licensing discussions at advanced stage
• International Phase III TRIST trial for renal cancer in progress
• FDA Special Protocol Assessment for Phase III TRIST trial
• Positive recommendation for orphan drug designation in EU for renal
cancer
• Encouraging results from Phase II trials in renal, colorectal and
prostate cancer
• UK clinical network committed to Phase III trial in colorectal cancer

MetXia(R) (cancer)

• Three dose levels of cyclophosphamide alongside MetXia successfully
evaluated in second stage of Phase II trial in pancreatic cancer

Targeted Antibody Therapy/CME-548 (cancer)

• Wyeth completed key preclinical studies

ProSavin(R) (Parkinson's disease)

• ProSavin outperformed standard treatment in preclinical studies
• Manufacturing of clinical material initiated in GMP facility
• Regulatory process for start of clinical trials underway

RetinoStat(R) (retinopathy)

• Preclinical results with optimised clinical candidate confirmed efficacy
• Preparations for clinical trials initiated

StarGen(TM) (Stargardt's disease)

• Preclinical programme initiated in collaboration with the Foundation
Fighting Blindness

Technology licensing

• LentiVector(R) technology licensing agreement with GlaxoSmithKline

[BrauchGeld]

Oxford schliesst 518 mio€ deal mit Sanofi-Aventis ab.


Oxford Biomedica, Sanofi sign cancer drug deal worth up to 518 mln euro

LONDON (AFX) - Oxford Biomedica PLC has licensed its experimental cancer therapy TroVax to France's Sanofi-Aventis, in a long-awaited deal that could be worth up to 518 mln eur to the UK small-cap drug developer.

Oxford will receive an initial payment of 29 mln eur, and further near-term payments of 19 mln, on milestones linked to the ongoing phase III study of the drug in renal cancer.

The company is also entitled to escalating royalties on global sales, and to further undisclosed commercial milestones when net sales reach certain levels. Additional payments will be made if regulatory milestones are achieved in other cancer types.

Analyst Jon Senior at Evolution Securities said the deal could be the largest out-licensing deal, in terms of headline numbers, struck by a UK biotechnology company.

"It's a fantastic deal. If you add in sales milestones, it could be worth more than 1 bln usd," he said.

He has raised his price target on the stock to 61 pence on the news, from 45, and retained an add recommendation.

At 9.00 am Oxford shares were trading a penny higher at 53, valuing the company at 280 mln stg. The stock has surged 30 pct in the last three months in anticipation of the deal, which the group has been negotiating for over a year.

Chief executive Alan Kingsman said the terms were as good as they could have hoped.

"We couldn't have wished for a better partner. Sanofi are absolute experts in the field, and they've recognised that TroVax is an exceptional opportunity."

Sanofi is the world's second-biggest maker of oncology drugs, and is very strong in vaccines.

TroVax is a type of cancer vaccine, in that it stimulates the body to produce an immune response to a specific antigen found on many tumours. The company believes the therapy could be effective in most solid tumour types, including lung and breast.

The most advanced trials conducted so far are in renal cancer, with a final stage, phase III trial in progress. Phase II trials in colorectal and prostate cancer are also ongoing.

Under the deal, TroVax may be developed by Sanofi in any cancer setting.

Meanwhile, Oxford has retained an option to develop TroVax for other cancer types in exchange for enhanced financial returns, while Sanofi will keep all commercial rights. It has also retained an option to participate in the promotion of TroVax in the US and the European Union.